- Home
- DNTH vs DAKT Comparison
DNTH vs DAKT Comparison
Compare DNTH & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- DAKT
- Stock Information
- Founded
- DNTH 2015
- DAKT 1968
- Country
- DNTH United States
- DAKT United States
- Employees
- DNTH N/A
- DAKT N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- DAKT Office Equipment/Supplies/Services
- Sector
- DNTH Health Care
- DAKT Industrials
- Exchange
- DNTH Nasdaq
- DAKT Nasdaq
- Market Cap
- DNTH 657.0M
- DAKT 680.6M
- IPO Year
- DNTH N/A
- DAKT 1994
- Fundamental
- Price
- DNTH $17.39
- DAKT $14.84
- Analyst Decision
- DNTH Strong Buy
- DAKT Strong Buy
- Analyst Count
- DNTH 8
- DAKT 1
- Target Price
- DNTH $53.00
- DAKT $26.00
- AVG Volume (30 Days)
- DNTH 255.5K
- DAKT 510.2K
- Earning Date
- DNTH 05-12-2025
- DAKT 06-25-2025
- Dividend Yield
- DNTH N/A
- DAKT N/A
- EPS Growth
- DNTH N/A
- DAKT N/A
- EPS
- DNTH N/A
- DAKT 0.04
- Revenue
- DNTH $6,524,000.00
- DAKT $799,806,000.00
- Revenue This Year
- DNTH N/A
- DAKT N/A
- Revenue Next Year
- DNTH N/A
- DAKT $4.86
- P/E Ratio
- DNTH N/A
- DAKT $406.38
- Revenue Growth
- DNTH 102.36
- DAKT N/A
- 52 Week Low
- DNTH $13.37
- DAKT $10.24
- 52 Week High
- DNTH $32.27
- DAKT $19.89
- Technical
- Relative Strength Index (RSI)
- DNTH 35.86
- DAKT 55.21
- Support Level
- DNTH $17.40
- DAKT $15.10
- Resistance Level
- DNTH $18.45
- DAKT $16.14
- Average True Range (ATR)
- DNTH 1.21
- DAKT 0.59
- MACD
- DNTH -0.22
- DAKT -0.05
- Stochastic Oscillator
- DNTH 10.60
- DAKT 36.27
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About DAKT Daktronics Inc.
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.